细胞疗法与人类的Interleukin 10产生ILC2s增强了岛屿功能,并抑制了异体移植的排斥

Sarah J Colpitts1, Sinthuja Jegatheeswaran1, Amanda Oakie2

  • 1Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Toronto General Hospital Research Institute, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.

概括

人类IL-10生产的II组先天性淋巴细胞 (ILC2s) 显示出作为细胞疗法的前景. 这些细胞增强了小岛的功能,并防止了移植模型中的排斥,这表明1型糖尿病治疗的潜力.